Eisai presented new analyses of ARIA and QOL on lecanemab in CLARITY AD study at the AD/PD 2023 meeting.
Eisai Co., Ltd. and Biogen Inc.: announced that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL), from the results of Eisai’s Phase III Clarity AD study of lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (A beta) protofibril antibody, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases annual meeting AD/PD